Eagle Global Advisors LLC Makes New $266,000 Investment in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Eagle Global Advisors LLC purchased a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the fourth quarter, Holdings Channel.com reports. The firm purchased 480 shares of the company’s stock, valued at approximately $266,000.

Other institutional investors have also bought and sold shares of the company. Private Advisor Group LLC grew its position in shares of IDEXX Laboratories by 7.0% during the third quarter. Private Advisor Group LLC now owns 1,928 shares of the company’s stock valued at $843,000 after purchasing an additional 126 shares in the last quarter. US Bancorp DE grew its position in shares of IDEXX Laboratories by 0.4% during the third quarter. US Bancorp DE now owns 19,318 shares of the company’s stock valued at $8,447,000 after purchasing an additional 76 shares in the last quarter. Signaturefd LLC grew its position in shares of IDEXX Laboratories by 5.3% during the third quarter. Signaturefd LLC now owns 1,198 shares of the company’s stock valued at $524,000 after purchasing an additional 60 shares in the last quarter. NBC Securities Inc. purchased a new position in shares of IDEXX Laboratories during the third quarter valued at about $241,000. Finally, Ieq Capital LLC grew its position in shares of IDEXX Laboratories by 3.4% during the third quarter. Ieq Capital LLC now owns 5,982 shares of the company’s stock valued at $2,616,000 after purchasing an additional 199 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 0.1 %

NASDAQ IDXX traded up $0.40 during trading on Friday, hitting $516.50. The stock had a trading volume of 267,200 shares, compared to its average volume of 546,767. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.16 and a current ratio of 1.57. The stock has a market capitalization of $42.66 billion, a price-to-earnings ratio of 50.00, a P/E/G ratio of 4.21 and a beta of 1.27. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39. The stock has a 50 day simple moving average of $509.96 and a 200 day simple moving average of $522.68.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Wednesday, May 1st. The company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.13. The business had revenue of $964.10 million during the quarter, compared to the consensus estimate of $965.43 million. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.03 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Bruce L. Claflin sold 200 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $540.80, for a total transaction of $108,160.00. Following the completion of the sale, the director now owns 161 shares of the company’s stock, valued at $87,068.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.11% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

IDXX has been the subject of a number of research analyst reports. William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a research report on Tuesday, April 9th. JPMorgan Chase & Co. increased their price target on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Morgan Stanley lowered their price target on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a report on Tuesday, May 14th. Barclays lowered their price target on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a report on Thursday, May 2nd. Finally, Piper Sandler downgraded shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price target for the company. in a report on Tuesday, January 30th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $580.38.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.